Rejuvenation of T-Cells Results in Younger Epigenetic Age & Improved Anti-Tumor Functions In Vitro & In Vivo
Time: 11:00 am
day: Conference Day Two - Track A - AM
Details:
- Novel potential disruptive technology to rejuvenate T-cells across multiple therapeutic modalities
- Rejuvenated T-cells show younger epigenetic age, enhanced cell proliferation and cytokine release, and sustained antitumor activity in vitro and in vivo
- Rejuvenated TILs preserve polyclonal anti-tumor TCR repertoire and display improved antitumor properties
